Clinical trial NCT05074979: Telerehabilitation in COVID-19 Survivors
Official title: Determining the Effectiveness of Telerehabilitation in COVID-19 Survivors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Telerehabilitation
Keywords: COVID-19
telerehabilitation
COVID-19 Survivors
functional capacity
pulmonary functions
peripheral muscle oxygenation
home workout program
Lead sponsor: Bandırma Onyedi Eylül University
Sponsor class: OTHER
First posted: 2021-10-12
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study was carried out in the post-acute period of the telerehabilitation program in individuals with dyspnea who had COVID-19; It will be done to examine the effects on dyspnea, exercise capacity, respiratory functions, activities of daily living, muscle strength, muscle oxygenation, fatigue and quality of life parameters.


Eligibility criteria: Inclusion Criteria:

* Diagnosed with COVID-19 by Computed Tomography (CT) or PCR test between the ages of 18-75,
* Do not have any orthopedic or neurological disease that will affect exercise capacity,
* Individuals who can take and execute verbal orders,
* Have had COVID-19 and at least 2 weeks have passed since the completion of the treatment,
* Individuals who have a computer or smart phone with a camera and internet connection and have the ability to use it (the participant himself or one of his family members living in the same house),
* Individuals who are sedentary (those whose physical activity level is inactive according to the Turkish version of the International Physical Activity Questionnaire (UFAA)),
* Having dyspnea at level 2 or 3 on the Medical Research Council Dyspnea Scale.

Exclusion Criteria:

* Those who have not had COVID-19 or acute period patients who are experiencing COVID-19,
* Individuals who cannot be contacted,
* Individuals with chronic heart disease,
* Those with concomitant uncontrolled disease; uncontrolled hypertension (resting blood pressure ≥160 /100mmHg), uncontrolled diabetes (random instantaneous blood glucose\>16.7 mmol/l, HbA1C\>7.0%),
* Those with concomitant severe organic disease (unstable hemodynamic heart disease, heart failure causing movement limitation, unstable angina, MI or other cardiac disease in the last 12 years),
* Individuals with cerebrovascular disease in the last 6 months,
* Those with digestive system ulcer, thyroid dysfunction or active stage of tuberculosis,
* Patients with Chronic Kidney Failure stage 3 and above according to Glomerular Filtration Rate (GFR),
* Individuals who have undergone intraraticular medication or surgery from their lower extremities in the last 6 months,
* Individuals who cannot walk independently,
* Individuals with any mental illness that may prevent them from living independently or receiving treatment,
* Uncooperative individuals for assessment and rehabilitation programs,
* Those with alcohol or substance addiction,
* Those who are pregnant, suspected of pregnancy or considering becoming pregnant,
* Participants in another study within the last 3 months or currently.

Primary outcomes:
measure: Severity of dyspnea assessment
timeFrame: 6 weeks
measure: Physical activity level assessment
timeFrame: 6 weeks
measure: Cardiopulmonary endurance assessment
timeFrame: 6 weeks
measure: Evaluation of peripheral muscle oxygenation
timeFrame: 6 weeks
measure: Pulmonary function (slow vital capacity)
timeFrame: 6 weeks
measure: Pulmonary function (Forced vital capacity (FVC))
timeFrame: 6 weeks
measure: Respiratory Muscle Strength
timeFrame: 6 weeks
measure: Activities of daily living assessment
timeFrame: 6 weeks
measure: Muscle strength assessment
timeFrame: 6 weeks
measure: Perceived fatigue assessment
timeFrame: 6 weeks
measure: General fatigue assessment
timeFrame: 6 weeks
measure: Quality of life assessment
timeFrame: 6 weeks
measure: Pulmonary function (Forced expiratory volume in the first second (FEV1))
timeFrame: 6 weeks
measure: Pulmonary function (FEV1 / FVC)
timeFrame: 6 weeks
measure: Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%)
timeFrame: 6 weeks
measure: Pulmonary function (Peak flow rate (PEF)
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Balıkesir
country: Turkey
facility: Bandırma Onyedi Eylül University, Faculty of Health Sciences, Physiotherapy and Rehabilitation Department
state: Bandırma
Study officials:
References: